Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 15/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3264633 | 1.00 | KCNH2 (0.47) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL3264631 | 1.00 | KCNH2 (0.47) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL1750732 | 0.91 | PDE4B (0.51) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL1751490 | 0.91 | PDE4B (0.51) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL2783355 | 0.91 | REN (0.43) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL2783354 | 0.91 | REN (0.43) | KCNH2TACR1RENCYP3A4PDE4B | |
| SCHEMBL4100936 | 0.89 | KCNH2 (0.47) | KCNH2RENCYP3A4 | |
| SCHEMBL3050463 | 0.89 | KCNH2 (0.47) | KCNH2RENCYP3A4 | |
| SCHEMBL4100940 | 0.89 | KCNH2 (0.47) | KCNH2RENCYP3A4 | |
| SCHEMBL3053444 | 0.88 | REN (0.44) | KCNH2TACR1RENPDE4BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-20100063091-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100063091-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20100063091-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2010-03-11 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| WO-2008141462-A9 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008141462-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2008058387-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063091-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KCNH2 822/4885TACR1 133/4885REN 1/4885 |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | KCNH2 1032/4885TACR1 142/4885REN 1/4885 |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | KCNH2 1085/4885TACR1 126/4885REN 1/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | KCNH2 923/4885TACR1 53/4885REN 1/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KCNH2 1198/4885TACR1 205/4885REN 1/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | KCNH2 476/4885TACR1 44/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.